Mild community-acquired pneumonia diarrhea
Conditions
Interventions
Antibiotic treatment group:None
Antibiotic combined with Saccharomyces boulardii treatment group:None
Sponsors
Liuzhou People's Hospital
Eligibility
Sex/Gender
All
Age
No minimum to 12 Years
Inclusion criteria
Inclusion criteria: 1.Children aged 6 months to 12 years (including both ends), without a history of premature birth, regardless of gender; 2. The clinical diagnosis is mild CAP, and oral antibiotic treatment is required. 3. There were no symptoms of diarrhea before the use of antibiotics; 4. The patient or his/her legal guardian signs the informed consent.
Exclusion criteria
Exclusion criteria: 1.Diarrhea, including acute or chronic diarrhea, occurred three days before treatment. 2. Digestive tract malformations, digestive tract surgeries, congenital heart diseases, cardiac surgeries, rheumatoid heart diseases, infective endocarditis. 3. Grade II or above malnutrition (weight 25%-40% lower than normal, subcutaneous fat thickness of the abdominal wall less than 0.4cm, pale skin, dry hair, height lower than normal), rotavirus diarrhea, bacterial enteritis, bacillary dysentery, chemotherapy-related diarrhea. 4. Contraindications for the Saccharomyces boulardii powder group include: (1) Patients allergic to a certain component of this product. (2) Patients receiving intravenous infusion through central venous catheters. (3) Patients who are intolerant to fructose because this product contains fructose. (4) Patients with congenital galactosemia, glucose and galactose absorption disorders syndrome or lactase deficiency due to the presence of lactose in this product. 5. Currently receiving immunosuppressants. 6. Had received any probiotic preparations two weeks before enrollment. 7. Antibiotics have been used within 4 weeks before enrollment. 8. Receive treatment with traditional Chinese patent medicines that have the effect of causing diarrhea. The researchers believed that it was not suitable for enrollment. 9. The researchers considered it unsuitable for enrollment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of AAD in the two groups of children; | — |
Secondary
| Measure | Time frame |
|---|---|
| The severity of AAD;The incidence of adverse events in the two groups of children;Classification of intestinal flora imbalance; | — |
Countries
China
Contacts
Public ContactJin Ling
Liuzhou People's Hospital
Outcome results
None listed